Soligenix, Inc.
0.630.02 (2.92%)
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close0.61
Bid0.00 x
Ask0.00 x
52wk Range0.44 - 1.72
Day's Range0.61 - 0.63
Avg Vol (3m)88,322
As of 3:48 PM EDT. Market closed.
  • Zacks Small Cap Research3 days ago

    SNGX Receives Additional BARDA and NIAID Funding to Advance Development of OrbeShield® in GI ARS

    By Grant Zeng, CFA OBB:SNGX On July 25, 2016, Soligenix (OBB:SNGX) announced that the company has been granted additional funding from the Biomedical Advanced Research and Development Authority (BARDA) ...

  • Zacks Small Cap Research9 days ago

    SNGX Announces Positive Results of a Heat Stable Ebola Vaccine Formulation

    On July 18, 2016, Soligenix (SNGX) announced positive preliminary proof-of-concept results from a heat stable subunit Ebola vaccine. This is a collaboration with Axel Lehrer, PhD of the Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine (JABSOM), University of Hawaiʻi at Mānoa (UH Mānoa) and Hawaii Biotech, Inc. (HBI). Soligenix’s ThermoVax Technology is used in this collaboration and has identified a formulation that enhances the physical stability of the protein and may be dose sparing.